CagriSema FDA Review: What Approval Would Rest On
CagriSema — cagrilintide plus semaglutide — is under FDA review, not approved. REDEFINE 1 treatment-policy 20.4% at 68 weeks, and what a decision would still leave open.
Novo Nordisk has submitted a New Drug Application to the U.S. Food and Drug Administration for CagriSema, its combination of cagrilintide and semaglutide, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [fda-cagrisema-approval]. If approved, it would be the first fixed-dose combination of two distinct peptide mechanisms for obesity treatment. CagriSema is not currently approved by the FDA or any other regulator; a first decision is expected in late 2026.
What We Know
CagriSema combines a long-acting amylin analog (cagrilintide 2.4 mg) with the GLP-1 receptor agonist semaglutide 2.4 mg in a single once-weekly subcutaneous injection. The application rests on the REDEFINE clinical trial program [fda-cagrisema-approval].
In the pivotal REDEFINE 1 trial (NCT05567796, 3,417 adults without diabetes), the estimated mean percent change in body weight at week 68 was −20.4% with CagriSema versus −3.0% with placebo (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001) [redefine-trials]. The PubMed abstract fetched 2026-09-02 does not report monotherapy percents or a trial-product percent; this page does not quote them.
The full compound record sits in the CagriSema dossier; its two components have their own pages, semaglutide and cagrilintide. How cagrilintide compares with survodutide is the converting pair on this site — not a new GLP-1 rematch.
Complementary Mechanisms
Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin that contributes to satiety and slows gastric emptying. While amylin and GLP-1 have overlapping effects on appetite, they work through distinct receptor systems and brain regions, creating potential for synergy.
The combination was designed to provide more comprehensive appetite control than either mechanism alone. GLP-1 acts on hypothalamic and reward centers, while amylin primarily affects brainstem regions involved in meal termination. Together, they address multiple aspects of eating behavior.
The safety profile of CagriSema was consistent with the known effects of its components. Gastrointestinal adverse events were the most common side effects, occurring in 79.6% of the CagriSema group versus 39.9% on placebo in REDEFINE 1, and were mainly transient and mild-to-moderate in severity [redefine-trials].
What It Means
If approved, CagriSema would become one of the most effective single-injection options for obesity on the published REDEFINE 1 primary analysis (−20.4% vs −3.0% at 68 weeks) [redefine-trials].
An approval would intensify competition in the obesity drug market. Eli Lilly’s tirzepatide (Zepbound) currently offers the highest weight loss among approved single-agent medications. NCT06131437 is an 84-week open-label randomised trial of CagriSema versus tirzepatide (actual enrollment 809; primary outcome non-inferiority on percent weight change at week 84; COMPLETED; CT.gov hasResults false as of 2026-09-02), so this page does not quote a head-to-head percent.
The manufacturing complexity of combining two peptides in a single product may affect supply. Novo Nordisk has emphasized its expanded manufacturing infrastructure, but robust demand could still create availability challenges.
The Diabetes Programme Has Now Published
The REDEFINE trials answered the obesity question. A separate phase 3 programme, REIMAGINE, answered the type 2 diabetes question, and all three trials published in mid-2026.
| Trial | Population | Duration | Headline (efficacy estimand) |
|---|---|---|---|
| REIMAGINE 1 [reimagine-1] | 189 adults, T2D on diet and exercise | 40 weeks | HbA1c −1.8 points vs −0.1 placebo; body weight −13.8% vs −1.4% |
| REIMAGINE 2 [reimagine-2] | 2,713 adults, T2D, 30 countries | 68 weeks | HbA1c −1.91 points vs −1.75 for semaglutide alone (difference −0.16, 95% CI −0.27 to −0.05) |
| REIMAGINE 3 [reimagine-3] | 274 adults, T2D on stable basal insulin | 40 weeks | HbA1c −2.33 points (2.4 mg each) vs −0.66 placebo; body weight −10 to −12% |
REIMAGINE 2 is the most informative of the three: it is the first phase 3 head-to-head of the combination against each of its own components, and it produced the first phase 3 cagrilintide monotherapy comparator data. The margin over semaglutide alone was statistically significant and absolutely small.
All three report their primary glycaemic outcome on the efficacy estimand, so there is no treatment-policy figure to lead with — a difference worth stating whenever these numbers sit beside REDEFINE 1’s treatment-policy 20.4%.
A separate phase 1 study found that renal or hepatic impairment does not affect cagrilintide’s pharmacokinetics, safety or tolerability [cagrilintide-pk], closing a special-population gap.
What’s Next
The FDA decision is the near-term gating event; a first review decision is expected in late 2026. Any commercial launch, pricing and patient-support arrangements would follow an approval, not precede it.
Cardiovascular risk reduction is still open: REDEFINE 3 is an event-driven outcomes trial and has not reported.
Longer-term data collection continues through extension studies. Questions about weight maintenance after discontinuation, durability of metabolic improvements, and very long-term safety would be addressed through post-marketing requirements and ongoing research.
Regardless of the regulatory outcome, the REDEFINE program has already influenced development of other combination approaches. Multiple pharmaceutical companies have dual and triple-agonist programs at various stages, promising continued evolution in obesity pharmacotherapy.
This information is provided for educational purposes only and does not constitute medical advice.
Sources & Citations
- 2journalCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
redefine-trials
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.